FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR

The FDA approved a 150-mg dose of secukinumab (Cosentyx, Novartis) for polymyalgia rheumatica (PMR), making it the first anti-IL-17 biologic for this condition. The approval was based on the phase 3 REPLENISH trial, which showed higher remission rates with secukinumab plus a glucocorticoid taper compared to the taper alone. According to Novartis, this is the 11th US indication for secukinumab.

Original reporting
Published Nov 18, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 5:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR — source image
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

A first and only FDA approval for anti-IL-17 biologic therapy in PMR, supported by phase 3 REPLENISH results, creates a new commercial indication and may improve investor expectations for Cosentyx’s growth trajectory.

02

Market read

Traders can treat this as a regulatory catalyst for Novartis’ Cosentyx franchise, with potential sentiment lift from a first-in-class PMR label expansion.

03

What to watch

The article highlights efficacy and steroid reduction, but does not quantify pricing, reimbursement, or expected patient share, which are key drivers of near-term financial impact.

Relevance 7/10Novelty 3/10Timing: FDA approval reported today, before/at market open window

Background

Polymyalgia rheumatica (PMR) is commonly treated with long-term glucocorticoids, which carry significant risks; secukinumab is an anti-IL-17A monoclonal antibody already approved for other inflammatory conditions.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

FDA approved secukinumab (Cosentyx) for PMR, expanding Novartis’ IL-17 biologic label and adding a new US indication.

Expected impact

Likely positive bias as investors price in label expansion and reduced steroid burden for PMR patients.

Evidence & confidence

The article is a first-in-class FDA approval for a new indication, supported by phase 3 REPLENISH efficacy and safety data, which is typically market-moving for the sponsor’s product franchise.

Market effects

Strengthens the IL-17 biologics competitive narrative in inflammatory rheumatology and may shift expectations for steroid-sparing regimens.

Primarily US regulatory-driven, but can influence global payer and prescriber expectations for PMR treatment.

Could accelerate adoption discussions in other markets where Cosentyx is already approved for related inflammatory diseases.

Counterpoint

PMR is a steroid-dependent standard of care, so uptake may be slower than efficacy headlines suggest due to prescribing inertia, payer prior authorization, and long-term safety monitoring.

Key entities

  • Secukinumab (Cosentyx)

    Fully human monoclonal antibody that selectively inhibits IL-17A, now FDA-approved for PMR at a 150 mg dose.

  • Novartis

    Sponsor of Cosentyx; president US quoted on the approval and expansion to an 11th US indication.

  • REPLENISH trial

    Phase 3 study in recently relapsed PMR comparing secukinumab plus prednisone taper versus placebo plus taper.

Related articles

$NVSMed

Cosentyx Wins FDA Approval for Polymyalgia Rheumatica Patients Who Cannot Taper Steroids, Doubling Sustained Remission in Trial

Novartis' Cosentyx (secukinumab) 150 mg received FDA approval for polymyalgia rheumatica in patients who cannot taper steroids. The approval follows a trial where 40.5% of patients on Cosentyx achieved sustained remission at one year, compared to 20.5% on placebo. Cosentyx is the first IL-17 blocking biologic approved for this condition, according to Novartis.

$NVSMed

Novartis reports positive phase 3 data on ianalumab for Sjögren’s

Novartis reported positive long-term phase 3 data for ianalumab in Sjögren’s disease, showing improved disease activity and a favorable safety profile. The FDA granted Breakthrough Therapy Designation in January, with a decision expected this year. Ianalumab is also being investigated for other autoimmune diseases. Novartis aims to address the unmet need for disease-modifying treatments in Sjögren’s.

$NVSMed

FDA Clears Secukinumab for Use in Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) for treating polymyalgia rheumatica (PMR) in adults unresponsive to corticosteroids. The approval follows positive phase 3 REPLENISH trial results, showing sustained remission rates of 41.2% and 40.6% for 300 mg and 150 mg doses, respectively, compared to 20.4% for placebo. Secukinumab is already approved for several other inflammatory conditions.

$NVSMed

FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica

The FDA approved Novartis' secukinumab (Cosentyx) 150 mg for polymyalgia rheumatica (PMR) in adults with inadequate corticosteroid response. The approval follows phase 3 trial results showing sustained remission in 40.5% of patients vs. 20.5% on placebo. Secukinumab is the first IL-17 biologic approved for PMR, offering a new treatment option with a steroid-sparing effect.